{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:43:16Z","timestamp":1788583396106,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra that primarily affects movement control. Neuroinflammation plays a pivotal role in driving the disease\u2019s progression. The persistent inflammatory state in the brain exacerbates neuronal damage, creating a cycle that perpetuates the neurodegenerative process. Glucocorticoids, such as dexamethasone, have potent anti-inflammatory properties and have been studied for their neuroprotective potential in different neurodegenerative diseases. However, their specific impact on PD remains unclear. This study aimed to evaluate the impact of dexamethasone on a neuromelanin (NM)-driven model of PD. We demonstrated that dexamethasone administration significantly improved motor function and preserved dopaminergic neuron compared to untreated controls in our study. These neuroprotective effects were mediated, at least in part, by suppressing reactive microglia and reducing the infiltration of peripheral immune cells into the brain. Our findings underscore the potential therapeutic benefits of dexamethasone in mitigating neuroinflammation and maintaining neuronal integrity in a NM-driven model of PD. These results advocate for further investigation into glucocorticoid-based therapies as adjunctive treatments for PD, particularly in scenarios where neuroinflammation contributes prominently to disease progression.<\/jats:p>","DOI":"10.1007\/s11481-024-10164-4","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T02:41:37Z","timestamp":1734144097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Neuroprotective Effects of Dexamethasone in a Neuromelanin-Driven Parkinson\u2019s Disease Model"],"prefix":"10.1007","volume":"20","author":[{"given":"M.","family":"Garcia-Gomara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Juan-Palencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cuadrado-Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garcia-Osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"key":"10164_CR1","doi-asserted-by":"publisher","unstructured":"Abellanas MA, Zamarbide M, Basurco L, Luquin E, Garcia-Granero M, Clavero P, Martin-Uriz S, Vilas P, Mengual A, Hervas-Stubbs E, Aymerich S, M.S (2019) Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions. J Neuroinflammation 16. https:\/\/doi.org\/10.1186\/S12974-019-1628-8","DOI":"10.1186\/S12974-019-1628-8"},{"key":"10164_CR2","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/GLIA.23199","volume":"65","author":"H Aono","year":"2017","unstructured":"Aono H, Choudhury ME, Higaki H, Miyanishi K, Kigami Y, Fujita K, Akiyama JI, Takahashi H, Yano H, Kubo M, Nishikawa N, Nomoto M, Tanaka J (2017) Microglia may compensate for dopaminergic neuron loss in experimental parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus. Glia 65:1833\u20131847. https:\/\/doi.org\/10.1002\/GLIA.23199","journal-title":"Glia"},{"key":"10164_CR3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1046\/J.1471-4159.1998.71041635.X","volume":"71","author":"N Aubin","year":"1998","unstructured":"Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635\u20131642. https:\/\/doi.org\/10.1046\/J.1471-4159.1998.71041635.X","journal-title":"J Neurochem"},{"key":"10164_CR4","doi-asserted-by":"publisher","unstructured":"Basurco L, Abellanas MA, Ayerra L, Conde E, Vinueza-Gavilanes R, Luquin E, Vales A, Vilas A, Martin\u2010Uriz PS, Tamayo I, Alonso MM, Hernaez M, Gonzalez\u2010Aseguinolaza G, Clavero P, Mengual E, Arrasate M, Herv\u00e1s\u2010Stubbs S, Aymerich MS (2023) Microglia and astrocyte activation is region-dependent in the \u03b1-synuclein mouse model of Parkinson\u2019s disease. Glia 71 https:\/\/doi.org\/10.1002\/GLIA.24295","DOI":"10.1002\/GLIA.24295"},{"key":"10164_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/S00401-007-0250-5\/FIGURES\/3","volume":"114","author":"TG Beach","year":"2007","unstructured":"Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH (2007) Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol 114:419\u2013424. https:\/\/doi.org\/10.1007\/S00401-007-0250-5\/FIGURES\/3","journal-title":"Acta Neuropathol"},{"key":"10164_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1042\/BST0351127","volume":"35","author":"ML Block","year":"2007","unstructured":"Block ML, Hong JS (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35:1127\u20131132. https:\/\/doi.org\/10.1042\/BST0351127","journal-title":"Biochem Soc Trans"},{"key":"10164_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1172\/JCI36470","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard V, Combadi\u00e8re B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4\u2009+\u2009lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182\u2013192. https:\/\/doi.org\/10.1172\/JCI36470","journal-title":"J Clin Invest"},{"key":"10164_CR8","doi-asserted-by":"publisher","unstructured":"Carballo-Carbajal I, Laguna A, Romero-Gim\u00e9nez J, Cuadros T, Bov\u00e9 J, Martinez-Vicente M, Parent A, Gonzalez-Sepulveda M, Pe\u00f1uelas N, Torra A, Rodr\u00edguez-Galv\u00e1n B, Ballabio A, Hasegawa T, Bortolozzi A, Gelpi E, Vila M (2019) Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson\u2019s disease pathogenesis. Nat Commun 10. https:\/\/doi.org\/10.1038\/S41467-019-08858-Y","DOI":"10.1038\/S41467-019-08858-Y"},{"issue":"1","key":"10164_CR9","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/J.PARKRELDIS.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(1):S30\u2013S33. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2017.07.033","journal-title":"Parkinsonism Relat Disord"},{"key":"10164_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0B013E3181D5A4A3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74:995\u20131002. https:\/\/doi.org\/10.1212\/WNL.0B013E3181D5A4A3","journal-title":"Neurology"},{"key":"10164_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1212\/WNL.0B013E31820F2D79","volume":"76","author":"X Gao","year":"2011","unstructured":"Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and risk of Parkinson disease. Neurology 76:863\u2013869. https:\/\/doi.org\/10.1212\/WNL.0B013E31820F2D79","journal-title":"Neurology"},{"key":"10164_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/GLIA.22580","volume":"62","author":"Y Gao","year":"2014","unstructured":"Gao Y, Ottaway N, Schriever SC, Legutko B, Garc\u00eda-C\u00e1ceres C, de la Fuente E, Mergen C, Bour S, Thaler JP, Seeley RJ, Filosa J, Stern JE, Perez-Tilve D, Schwartz MW, Tsch\u00f6p MH, Yi CX (2014) Hormones and Diet, but not body weight. Control Hypothalamic Microglial Activity Glia 62:17. https:\/\/doi.org\/10.1002\/GLIA.22580","journal-title":"Control Hypothalamic Microglial Activity Glia"},{"key":"10164_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/BRAIN\/AWAC445","volume":"146","author":"M Gonzalez-Sepulveda","year":"2023","unstructured":"Gonzalez-Sepulveda M, Compte J, Cuadros T, Nicolau A, Guillard-Sirieix C, Pe\u00f1uelas N, Lorente-Picon M, Parent A, Romero-Gim\u00e9nez J, Cladera-Sastre JM, Laguna A, Vila M (2023) In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson\u2019s disease. Brain 146:1040\u20131052. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC445","journal-title":"Brain"},{"key":"10164_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/NN.4222","volume":"19","author":"K Grabert","year":"2016","unstructured":"Grabert K, Michoel T, Karavolos MH, Clohisey S, Kenneth Baillie J, Stevens MP, Freeman TC, Summers KM, McColl BW (2016) Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci 19:504\u2013516. https:\/\/doi.org\/10.1038\/NN.4222","journal-title":"Nat Neurosci"},{"key":"10164_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.BRAINRES.2010.03.012","volume":"1329","author":"D Hinkerohe","year":"2010","unstructured":"Hinkerohe D, Smikalla D, Schoebel A, Haghikia A, Zoidl G, Haase CG, Schlegel U, Faustmann PM (2010) Dexamethasone prevents LPS-induced microglial activation and astroglial impairment in an experimental bacterial meningitis co-culture model. Brain Res 1329:45\u201354. https:\/\/doi.org\/10.1016\/J.BRAINRES.2010.03.012","journal-title":"Brain Res"},{"key":"10164_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(11)70065-7","author":"EC Hirsch","year":"2012","unstructured":"Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson\u2019s disease. Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/S1353-8020(11)70065-7. 18 Suppl 1","journal-title":"Parkinsonism Relat Disord"},{"key":"10164_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/S00210-019-01775-3","volume":"393","author":"B Hui","year":"2020","unstructured":"Hui B, Yao X, Zhang L, Zhou Q (2020a) Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cells. Naunyn Schmiedebergs Arch Pharmacol 393:1761\u20131768. https:\/\/doi.org\/10.1007\/S00210-019-01775-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10164_CR18","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/S00210-019-01775-3","volume":"393","author":"B Hui","year":"2020","unstructured":"Hui B, Yao X, Zhang L, Zhou Q (2020b) Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cells. Naunyn Schmiedebergs Arch Pharmacol 393:1761\u20131768. https:\/\/doi.org\/10.1007\/S00210-019-01775-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10164_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/S00401-003-0766-2\/FIGURES\/6","volume":"106","author":"K Imamura","year":"2003","unstructured":"Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol 106:518\u2013526. https:\/\/doi.org\/10.1007\/S00401-003-0766-2\/FIGURES\/6","journal-title":"Acta Neuropathol"},{"key":"10164_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0165-5728(91)90119-R","volume":"34","author":"R Kiefer","year":"1991","unstructured":"Kiefer R, Kreutzberg GW (1991) Effects of dexamethasone on microglial activation in vivo: selective downregulation of major histocompatibility complex class II expression in regenerating facial nucleus. J Neuroimmunol 34:99\u2013108. https:\/\/doi.org\/10.1016\/0165-5728(91)90119-R","journal-title":"J Neuroimmunol"},{"key":"10164_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.intimp.2004.05.006","volume":"4","author":"I Kurkowska-Jastrz\u0229bska","year":"2004","unstructured":"Kurkowska-Jastrz\u0229bska I, Litwin T, Joniec I, Ciesielska A, Przyby\u0142kowski A, Cz\u0142onkowski A, Cz\u0142onkowska A (2004) Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson\u2019s disease. Int Immunopharmacol 4:1307\u20131318. https:\/\/doi.org\/10.1016\/j.intimp.2004.05.006","journal-title":"Int Immunopharmacol"},{"key":"10164_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.PARKRELDIS.2020.11.011","volume":"82","author":"S Lavisse","year":"2021","unstructured":"Lavisse S, Goutal S, Wimberley C, Tonietto M, Bottlaender M, Gervais P, Kuhnast B, Peyronneau MA, Barret O, Lagarde J, Sarazin M, Hantraye P, Thiriez C, Remy P (2021) Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism Relat Disord 82:29\u201336. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2020.11.011","journal-title":"Parkinsonism Relat Disord"},{"key":"10164_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0306-4522(90)90229-W","volume":"39","author":"LJ Lawson","year":"1990","unstructured":"Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151\u2013170. https:\/\/doi.org\/10.1016\/0306-4522(90)90229-W","journal-title":"Neuroscience"},{"key":"10164_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000325653","volume":"36","author":"AD Manthripragada","year":"2011","unstructured":"Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH, Ritz B (2011) Non-steroidal anti-inflammatory drug use and the risk of Parkinson\u2019s disease. Neuroepidemiology 36:155\u2013161. https:\/\/doi.org\/10.1159\/000325653","journal-title":"Neuroepidemiology"},{"key":"10164_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/GLIA.22935","volume":"64","author":"HL Martin","year":"2016","unstructured":"Martin HL, Santoro M, Mustafa S, Riedel G, Forrester JV, Teismann P (2016) Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson\u2019s disease. Glia 64:386. https:\/\/doi.org\/10.1002\/GLIA.22935","journal-title":"Glia"},{"key":"10164_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, Hiliare S, Shprecher MH, Lee D, Dawson S, Roschke TM, Kieburtz V, K (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"key":"10164_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/GLIA.440070114","volume":"7","author":"PL McGeer","year":"1993","unstructured":"McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG (1993) Microglia in degenerative neurological disease. Glia 7:84\u201392. https:\/\/doi.org\/10.1002\/GLIA.440070114","journal-title":"Glia"},{"key":"10164_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/J.VETPAR.2007.08.017","volume":"149","author":"TA Miller","year":"2007","unstructured":"Miller TA, Schaefer FW (2007) Changes in mouse circulating leukocyte numbers in C57BL\/6 mice immunosuppressed with dexamethasone for Cryptosporidium parvum oocyst production. Vet Parasitol 149:147\u2013157. https:\/\/doi.org\/10.1016\/J.VETPAR.2007.08.017","journal-title":"Vet Parasitol"},{"key":"10164_CR29","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/SJ.BJP.0702423","volume":"126","author":"L Minghetti","year":"1999","unstructured":"Minghetti L, Nicolini A, Polazzi E, Greco A, Perretti M, Parente L, Levi G (1999) Down-regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol 126:1307. https:\/\/doi.org\/10.1038\/SJ.BJP.0702423","journal-title":"Br J Pharmacol"},{"key":"10164_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1096\/FJ.03-0501FJE","volume":"18","author":"MC Morale","year":"2004","unstructured":"Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L\u2019Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B (2004) Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J 18:164\u2013166. https:\/\/doi.org\/10.1096\/FJ.03-0501FJE","journal-title":"FASEB J"},{"key":"10164_CR31","doi-asserted-by":"publisher","first-page":"32312","DOI":"10.1074\/JBC.273.48.32312","volume":"273","author":"R Newton","year":"1998","unstructured":"Newton R, Seybold J, Kuitert LME, Bergmann M, Barnes PJ (1998) Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 273:32312\u201332321. https:\/\/doi.org\/10.1074\/JBC.273.48.32312","journal-title":"J Biol Chem"},{"key":"10164_CR50","unstructured":"Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press,San Diego"},{"key":"10164_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ANTIOX9080743","volume":"9","author":"DSA Simpson","year":"2020","unstructured":"Simpson DSA, Oliver PL (2020) ROS Generation in Microglia: understanding oxidative stress and inflammation in neurodegenerative disease. Antioxid (Basel Switzerland) 9:1\u201327. https:\/\/doi.org\/10.3390\/ANTIOX9080743","journal-title":"Antioxid (Basel Switzerland)"},{"key":"10164_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.BRAINRESBULL.2011.10.004","volume":"87","author":"JA Smith","year":"2012","unstructured":"Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87:10. https:\/\/doi.org\/10.1016\/J.BRAINRESBULL.2011.10.004","journal-title":"Brain Res Bull"},{"key":"10164_CR34","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/FEBS.14607","volume":"285","author":"DJ Surmeier","year":"2018","unstructured":"Surmeier DJ (2018) Determinants of dopaminergic neuron loss in Parkinson\u2019s disease. FEBS J 285:3657\u20133668. https:\/\/doi.org\/10.1111\/FEBS.14607","journal-title":"FEBS J"},{"key":"10164_CR35","doi-asserted-by":"publisher","unstructured":"Walker DG, Lue LF (2015) Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther 7. https:\/\/doi.org\/10.1186\/S13195-015-0139-9","DOI":"10.1186\/S13195-015-0139-9"},{"key":"10164_CR36","doi-asserted-by":"publisher","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4. https:\/\/doi.org\/10.1186\/S40035-015-0042-0","DOI":"10.1186\/S40035-015-0042-0"},{"key":"10164_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/FJ.02-0314FJE","volume":"17","author":"H Wilms","year":"2003","unstructured":"Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R (2003) Activation of microglia by human neuromelanin is NF-\u03baB-dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson\u2019s disease. FASEB J 17:1\u201320. https:\/\/doi.org\/10.1096\/FJ.02-0314FJE","journal-title":"FASEB J"},{"key":"10164_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/J.TINS.2003.08.009","volume":"26","author":"L Zecca","year":"2003","unstructured":"Zecca L, Zucca FA, Wilms H, Sulzer D (2003) Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 26:578\u2013580. https:\/\/doi.org\/10.1016\/J.TINS.2003.08.009","journal-title":"Trends Neurosci"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-024-10164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-024-10164-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-024-10164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T03:03:15Z","timestamp":1734145395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-024-10164-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10164"],"URL":"https:\/\/doi.org\/10.1007\/s11481-024-10164-4","relation":{},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2"}}